Ajanta Pharma promoter Ravi Agrawal, acting as trustee for the Ravi Agrawal Trust, has announced the release of a pledge on 1,60,000 equity shares. This action was taken due to ‘Excess Pledge’ and involves shares held in the company. The disclosure, made on June 30, 2026, complies with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, detailing the specifics of the released encumbrance.
Promoter Encumbrance Update
Ravi Agrawal, acting as the promoter and trustee for the Ravi Agrawal Trust, has officially disclosed the release of a pledge on a significant block of shares in Ajanta Pharma Limited. The total number of equity shares released from the pledge is 1,60,000. This release signifies a change in the encumbrance status of these shares, as reported on June 30, 2026.
Reason for Release
The stated reason for the release of this pledge is categorized as ‘Excess Pledge’. This indicates that the encumbered shares were beyond a certain threshold deemed necessary or permissible, prompting the partial release. The company’s scrip codes for BSE and NSE are AJANTPHARM 532331 and AJANTPHARM EQ, respectively.
Regulatory Disclosure
This disclosure has been made in accordance with Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filing provides a detailed account of the release of the pledge on shares held by the promoter. The trustee, Ravi Agrawal, has formally communicated this information to both the BSE Limited and the National Stock Exchange of India.
Shareholding Details (Post-Release)
The detailed disclosures highlight that prior to the release, Ravi P. Agrawal, trustee for Ravi Agrawal Trust, had 1,697,696 shares encumbered, representing 1.36% of the total share capital. Following the release of 1,60,000 shares, the encumbered amount stands at 1,537,696 shares, which now constitutes 1.23% of the total share capital.
Source: BSE
